Passage BIO, Inc.
Passage BIO, Inc. is a U.S.-based clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. The company was incorporated in Delaware and is centered on advancing licensed technology, conducting clinical trials, and manufacturing clinical supply for its product candidates.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueOne-time genetic medicines designed to treat neurodegenerative diseases, including PBFT02.
Research, assay development, and preclinical studies supporting pipeline advancement.
Manufacturing of clinical-grade material and supply for ongoing trials.
Development and use of in-licensed intellectual property for CNS gene therapy programs.
Customers
Passage BIO’s direct customers are not commercial end-users today; its work is aimed at regulators, clinical investigators, and eventually physicians and patients in neurodegenerative disease markets. In the current stage, the company’s economic value is tied to advancing product candidates through clinical development and generating data that can support future partnering or commercialization.
They run studies of PBFT02 and related programs and need clinical supply, protocols, and support.
FDA and other agencies evaluate the company’s clinical and manufacturing data for approval pathways.
The eventual end users of approved gene therapies for CNS disorders such as frontotemporal dementia.
Biopharma collaborators or licensors that may support development, funding, or commercialization.
Strategy
The company’s strategy is to advance PBFT02 and other gene therapy programs through clinical development, with a focus on neurodegenerative diseases and CNS delivery. It also seeks to preserve flexibility through collaborations, in-licensing, and other strategic transactions while it funds development through external capital.
Clinical data are the main driver of value for a pre-commercial gene therapy company.
Development-stage operations require external funding before product revenue exists.
Gene therapies require validated, reproducible manufacturing and release testing.
Geography
Passage BIO is incorporated in Delaware and operates as a U.S.-based development-stage biotechnology company. Its clinical and manufacturing activities are centered on the United States, while future commercialization would depend on regulatory and reimbursement conditions in the U.S. and other markets.
Risks
Passage BIO faces the typical risks of a clinical-stage biotechnology company: clinical failure, regulatory delay, manufacturing complexity, and the need for repeated external financing. Because it has no commercial product revenue, its business model is highly dependent on successful trial outcomes, access to capital, and eventual reimbursement for any approved therapy.
- Single-program concentrationImpact: HighLikelihood: Medium
PBFT02 is currently the only clinical-stage product candidate, so setbacks would have outsized impact.
Exposure: Pipeline concentration
- Clinical development failureImpact: HighLikelihood: Medium
Gene therapy programs can fail on safety, efficacy, dosing, or delivery even after early promise.
Exposure: PBFT02 and CNS gene therapy platform
- Manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
The company relies on third parties for clinical supply, testing, and process development.
Exposure: Catalent Maryland and external labs
- Financing riskImpact: HighLikelihood: Medium
Operations are funded through external capital until product revenue, if any, is generated.
Exposure - Reimbursement and market access riskImpact: MediumLikelihood: Medium
Even if approved, payors may limit coverage or pricing for high-cost gene therapies.
Exposure: U.S. and international commercialization
Accounting
Judgemental itemsMost spending is tied to clinical and preclinical programs, so timing of expense recognition drives reported losses.
Impact: Clinical trial, manufacturing, and development costs
The company must estimate unpaid external trial, testing, and supply costs at period end.
Impact: Operating expenses and liabilities
If programs stall or data weaken, capitalized or acquired rights may lose value.
Impact: Balance sheet carrying values and earnings
Equity awards are common in development-stage biotech and can be a meaningful non-cash expense.
Impact: Operating expense and diluted share count
Similar listed companies
Publicly listed companies with a comparable business focus.
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Last updated: 24/09/2026